出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年1月
Theranostics Market – Global Forecasts to 2028
セラノスティクス市場 : 製品［画像診断（PET、CT、MRI）、放射性医薬品（Lu-177、Sm-153、Ra-223、I-131）、バイオマーカースクリーニング、ソフトウェア］、用途（前立腺がん、骨転移）、ステークホルダーの期待 – 2028年までの世界予測
Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations – Global Forecast to 2028
| ページ数 | 194 |
| 図表数 | 134 |
| 種別 | 英文調査報告書 |
| 価格 |
世界のセラノスティクス市場は、2023年から2028年まで15.5%のCAGRで成長し、2023年の21億米ドルから2028年までに43億米ドルに達すると予測されています。
MarketsandMarkets（マーケッツアンドマーケッツ）「セラノスティクス市場 : 製品［画像診断（PET、CT、MRI）、放射性医薬品（Lu-177、Sm-153、Ra-223、I-131）、バイオマーカースクリーニング、ソフトウェア］、用途（前立腺がん、骨転移）、ステークホルダーの期待 – 2028年までの世界予測 – Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations – Global Forecast to 2028」は世界のセラノスティクス市場を調査し、主要セグメント毎に分析・予測を行っています。
主な対象セグメント
- 製品
- 画像診断
- 放射性医薬品
- IVD／バイオマーカースクリーニング
- ソフトウェアとサービス
- 用途
- 前立腺がん
- 骨転移
- その他のがん
- その他の用途
- エンドユーザ
- 病院とがん治療センター
- セラノスティクスセンター
- 研究・アカデミックセンター
- 地域
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- フランス
- 英国
- その他の欧州
- アジア太平洋地域
- 日本
- 中国
- インド
- その他のアジア太平洋地域
- その他の地域（RoW）
- 北米
Report Overview
The global theranostics market is projected to reach USD 4.3 billion by 2028 from USD 2.1 billion in 2023, at a CAGR of 15.5% from 2023 to 2028.
Factors such as rising baby boomer population and advances in research and development of radiopharmceuticals are responsible for the increasing growth of this market. Increasing research and development activities, rising number of clinical trials, and government initiatives attributes to the growth of theranostics market.
“The radiopharmaceuticals segment held the largest share of the market in 2022.”
Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. The radiopharmaceuticals segment held the largest market share in 2022. The large share of this segment can be attributed to the rising adoption of theranostics and increasing prevalence of chronic diseases such as cancer.
“The prostate cancer application segment is projected to register the highest CAGR of the theranostics market by application during the forecast period.”
Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. The prostate cancer application segment is projected to register the highest CAGR of the theranostics market from 2023 to 2028. Factors such as rising number of cancer population and ongoing clinical trials to know the benefits of theranostics for other applications are driving the market growth.
“The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.”
The theranostics market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India is evolving at a rapid pace, leading to major investments by hospitals and other end users. These factors are anticipated to fuel the growth of theranostics market in this region.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: Director-level–14%, C-level–10%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Rest of the World- 8%
The prominent players in the theranostics market Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US) among others.
Research Coverage
This report studies the theranostics market based on product, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall theranostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
• Analysis of key drivers (growing geriatric population and rising prevalence of associated diseases, rising use of radiophamrceuticals, rising focus on precision medicine), restraints (short life of radiopharmceuticals, unfavourable reimbursement scenario), opportunities (growth opportunities in emerging countries, advances in research and development of radiopharmceuticals), and challenges (hospital budget cuts and high equipment costs) influencing the growth of the theranostics market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the theranostics market
• Market Development: Comprehensive information about lucrative markets–the report analyses the theranostics market across varied regions
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the theranostics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US).
Table of Contents
1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.3 INCLUSIONS & EXCLUSIONS 22
1.4 MARKET SEGMENTATION 23
1.4.1 MARKETS COVERED 23
1.4.2 REGIONS COVERED 23
1.4.3 YEARS CONSIDERED 24
1.4.4 CURRENCY CONSIDERED 24
1.5 RESEARCH LIMITATIONS 24
1.6 STAKEHOLDERS 25
1.7 RECESSION IMPACT: THERANOSTICS MARKET 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
FIGURE 1 RESEARCH DESIGN METHODOLOGY 26
2.1.1 SECONDARY DATA 27
2.1.2 PRIMARY DATA 28
2.1.2.1 Primary sources 28
2.1.2.2 Key industry insights 29
2.1.2.3 Breakdown of primaries 29
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 29
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 31
2.2.1 BOTTOM-UP APPROACH 31
2.2.1.1 Approach 1: Company revenue estimation approach 32
FIGURE 5 COMPANY REVENUE ESTIMATION 32
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG 33
2.2.1.2 Approach 2: Patient population-based market estimation 33
FIGURE 7 BOTTOM-UP APPROACH: THERANOSTICS MARKET 34
2.2.1.3 Growth forecast 34
2.2.1.4 CAGR projections 35
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 35
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 35
FIGURE 9 DATA TRIANGULATION METHODOLOGY 36
2.3.1 MARKET SHARE ESTIMATION 36
2.4 STUDY ASSUMPTIONS 37
2.4.1 MARKET ASSUMPTIONS 37
2.4.2 GROWTH RATE ASSUMPTIONS 37
2.5 RISK ASSESSMENT 38
TABLE 1 RISK ASSESSMENT: THERANOSTICS MARKET 38
2.6 IMPACT OF ECONOMIC RECESSION ON THERANOSTICS MARKET 38
3 EXECUTIVE SUMMARY 39
FIGURE 10 THERANOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 39
FIGURE 11 THERANOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 40
FIGURE 12 THERANOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 40
FIGURE 13 REGIONAL SNAPSHOT OF THERANOSTICS MARKET 41
4 PREMIUM INSIGHTS 42
4.1 THERANOSTICS MARKET OVERVIEW 42
FIGURE 14 RISING PREVALENCE OF CANCER AND GROWING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET 42
4.2 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT (USD MILLION) 43
FIGURE 15 RADIOPHARMACEUTICALS TO COMMAND LARGEST MARKET SHARE IN NORTH AMERICAN THERANOSTICS MARKET DURING FORECAST PERIOD 43
4.3 EUROPE: THERANOSTICS MARKET, BY APPLICATION (USD MILLION) 44
FIGURE 16 PROSTATE CANCER TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 44
4.4 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER (USD MILLION) 44
FIGURE 17 HOSPITALS AND CANCER CARE CENTERS TO COMMAND LARGEST SHARE IN ASIA PACIFIC MARKET DURING FORECAST PERIOD 44
4.5 GEOGRAPHIC SNAPSHOT: THERANOSTICS MARKET 45
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
5.2 MARKET DYNAMICS 46
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: THERANOSTICS MARKET 46
5.2.1 DRIVERS 47
5.2.1.1 Growing geriatric population and rising prevalence of target diseases 47
5.2.1.2 Increasing use of radiopharmaceuticals in neurological applications 47
5.2.1.3 Growing focus on precision medicine 47
5.2.2 RESTRAINTS 48
5.2.2.1 Short half-life of radiopharmaceuticals 48
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS 48
5.2.2.2 Unfavorable healthcare reimbursement scenario 49
5.2.3 OPPORTUNITIES 49
5.2.3.1 Growth opportunities in emerging economies 49
5.2.3.2 Rising number of R&D programs for radiopharmaceuticals 49
5.2.4 CHALLENGES 50
5.2.4.1 Hospital budget cuts and high equipment costs 50
5.3 PRICING ANALYSIS 50
FIGURE 20 AVERAGE SELLING PRICE FOR RADIOPHARMACEUTICALS 51
TABLE 3 AVERAGE COST FOR THERANOSTICS TREATMENT, BY REGION 52
5.4 VALUE CHAIN ANALYSIS 52
FIGURE 21 VALUE CHAIN ANALYSIS: THERANOSTICS MARKET 52
5.5 ECOSYSTEM/MARKET MAP 53
5.6 SUPPLY CHAIN ANALYSIS 53
5.6.1 PROMINENT COMPANIES 53
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 54
5.6.3 END USERS 54
FIGURE 22 SUPPLY CHAIN ANALYSIS: THERANOSTICS MARKET 54
5.7 PORTER’S FIVE FORCES ANALYSIS 54
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: THERANOSTICS MARKET 55
5.7.1 INTENSITY OF COMPETITIVE RIVALRY 55
5.7.2 BARGAINING POWER OF SUPPLIERS 55
5.7.3 BARGAINING POWER OF BUYERS 55
5.7.4 THREAT OF SUBSTITUTES 56
5.7.5 THREAT OF NEW ENTRANTS 56
5.8 REGULATORY LANDSCAPE 56
5.8.1 NORTH AMERICA 56
5.8.1.1 US 56
5.8.1.2 Canada 56
5.8.2 EUROPE 57
5.8.3 ASIA PACIFIC 57
5.8.3.1 Australia 57
5.8.3.2 India 57
5.8.3.3 China 58
5.8.4 REST OF THE WORLD 58
5.8.4.1 Turkey 58
5.8.4.2 UAE 58
5.8.4.3 South Africa 58
TABLE 5 REGULATORY AGENCIES AND GUIDELINES 59
5.9 TIMELINE FOR THERANOSTICS MARKET 61
5.10 REIMBURSEMENT ANALYSIS 61
TABLE 6 MEDICAL REIMBURSEMENT CODES FOR THERANOSTICS IN US, 2022 62
5.11 TRADE ANALYSIS 62
5.11.1 TRADE ANALYSIS FOR THERANOSTICS MARKET 62
TABLE 7 IMPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND) 62
TABLE 8 EXPORT DATA FOR RADIOPHARMACEUTICALS, BY COUNTRY, 2018–2022 (USD THOUSAND) 63
5.12 PATENT ANALYSIS 64
FIGURE 23 TOP 10 PATENT APPLICANTS FOR THERANOSTICS (JANUARY 2012–DECEMBER 2022) 64
5.13 CASE STUDY ANALYSIS 65
TABLE 9 CASE STUDY 1: LUTETIUM-177-PSMA-617 FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER 65
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 65
5.14.1 KEY STAKEHOLDERS 65
TABLE 10 KEY STAKEHOLDERS AND THEIR REQUIREMENTS 65
5.14.2 IMPACT ANALYSIS OF KEY BUYING CRITERIA 66
TABLE 11 IMPACT OF KEY STAKEHOLDERS ON BUYING CRITERIA 66
5.15 KEY CONFERENCES & EVENTS 69
TABLE 12 LIST OF KEY CONFERENCES & EVENTS, 2023–2024 69
5.16 CLINICAL RESEARCH DATA FOR THERANOSTICS MARKET 70
6 THERANOSTICS MARKET, BY PRODUCT 73
6.1 INTRODUCTION 74
TABLE 13 THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 74
6.2 DIAGNOSTIC IMAGING 74
6.2.1 EASY ANALYSIS OF DISEASE CONDITIONS AND ACCURATE THERAPIES TO DRIVE MARKET 74
TABLE 14 THERANOSTICS MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2021–2028 (USD MILLION) 75
6.3 RADIOPHARMACEUTICALS 75
TABLE 15 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 75
TABLE 16 THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY REGION, 2021–2028 (USD MILLION) 76
6.3.1 LUTETIUM-177 76
6.3.1.1 Increasing incidence of neuroendocrine cancer to boost segment 76
TABLE 17 LUTETIUM-177 MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.3.1.2 Samarium-153 77
6.3.1.3 Rising incidence of bone metastasis to drive segment growth 77
TABLE 18 SAMARIUM-153 MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.3.1.4 Radium-223 78
6.3.1.4.1 Easy production of Radium-223 molecule to support market growth 78
TABLE 19 RADIUM-223 MARKET, BY REGION, 2021–2028 (USD MILLION) 78
6.3.1.5 Iodine-131 78
6.3.1.5.1 Increased applications in thyroid cancer and hyperthyroidism treatment to propel market 78
TABLE 20 IODINE-131 MARKET, BY REGION, 2021–2028 (USD MILLION) 79
6.3.1.6 Yttrium-90 79
6.3.1.6.1 Rising use in non-Hodgkin lymphoma and oncology radiotheranostics to drive segment 79
TABLE 21 YTTRIUM-90 MARKET, BY REGION, 2021–2028 (USD MILLION) 79
6.3.1.7 Other radiopharmaceuticals 80
TABLE 22 OTHER RADIOPHARMACEUTICALS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
6.4 IVD/BIOMARKER SCREENING 80
6.4.1 RISING ADOPTION OF THERANOSTICS TREATMENT TO SUPPORT MARKET GROWTH 80
TABLE 23 THERANOSTICS MARKET FOR IVD/BIOMARKER SCREENING, BY REGION, 2021–2028 (USD MILLION) 81
6.5 SOFTWARE & SERVICES 81
6.5.1 RISING USE OF NOVEL SOFTWARE AND INCREASING DEMAND FOR IMAGING SERVICES TO PROPEL MARKET 81
TABLE 24 THERANOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 82
7 THERANOSTICS MARKET, BY APPLICATION 83
7.1 INTRODUCTION 84
TABLE 25 THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 84
7.2 PROSTATE CANCER 84
7.2.1 RISING INCIDENCE OF PROSTATE CANCER AMONG MEN TO FUEL MARKET 84
TABLE 26 THERANOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 85
7.3 BONE METASTASIS 85
7.3.1 INTRODUCTION OF NOVEL MEDICAL THERAPIES TO DRIVE MARKET 85
TABLE 27 THERANOSTICS MARKET FOR BONE METASTASIS, BY REGION, 2021–2028 (USD MILLION) 86
7.4 OTHER CANCERS 86
TABLE 28 THERANOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 86
7.5 OTHER APPLICATIONS 87
TABLE 29 THERANOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 87
8 THERANOSTICS MARKET, BY END USER 88
8.1 INTRODUCTION 89
TABLE 30 THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 89
8.2 HOSPITALS AND CANCER CARE CENTERS 89
8.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW SYSTEMS TO DRIVE MARKET 89
TABLE 31 THERANOSTICS MARKET FOR HOSPITALS AND CANCER CARE CENTERS, BY REGION, 2021–2028 (USD MILLION) 90
8.3 THERANOSTICS CENTERS 91
8.3.1 GROWING FOCUS ON TARGETED THERAPIES AND RISING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET 91
TABLE 32 THERANOSTICS MARKET FOR THERANOSTICS CENTERS, BY REGION, 2021–2028 (USD MILLION) 91
8.4 RESEARCH AND ACADEMIC CENTERS 92
8.4.1 INCREASING COLLABORATIONS BETWEEN THERANOSTICS COMPANIES AND ACADEMIA TO SUPPORT MARKET GROWTH 92
TABLE 33 THERANOSTICS MARKET FOR RESEARCH AND ACADEMIC CENTERS, BY REGION, 2021–2028 (USD MILLION) 92
9 THERANOSTICS MARKET, BY REGION 93
9.1 INTRODUCTION 94
TABLE 34 THERANOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
9.2 NORTH AMERICA 94
FIGURE 24 NORTH AMERICA: CANCER PREVALENCE, 2012–2020 95
FIGURE 25 NORTH AMERICA: THERANOSTICS MARKET SNAPSHOT (2022) 96
TABLE 35 NORTH AMERICA: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 36 NORTH AMERICA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 97
TABLE 37 NORTH AMERICA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 97
TABLE 38 NORTH AMERICA: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 39 NORTH AMERICA: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 98
9.3 NORTH AMERICA: RECESSION IMPACT 98
9.3.1 US 99
9.3.1.1 US to dominate North American theranostics market during forecast period 99
TABLE 40 US: KEY MACROINDICATORS 99
TABLE 41 US: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 100
TABLE 42 US: THERANOSTICS MARKET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 100
9.3.2 CANADA 101
9.3.2.1 Rising geriatric population and increasing number of initiatives for medical isotope development to drive market 101
TABLE 43 CANADA: KEY MACROINDICATORS 101
TABLE 44 CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 102
TABLE 45 CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 102
9.4 EUROPE 102
TABLE 46 EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 47 EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103
TABLE 48 EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 49 EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 104
TABLE 50 EUROPE: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 104
9.4.1 EUROPE: RECESSION IMPACT 105
9.4.2 GERMANY 105
9.4.2.1 Well-established healthcare system and increased geriatric population to drive market 105
TABLE 51 GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 106
TABLE 52 GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 106
9.4.3 UK 107
9.4.3.1 Increasing government funding in diagnostic imaging to support market growth 107
TABLE 53 UK: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108
TABLE 54 UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 108
9.4.4 FRANCE 108
9.4.4.1 Favorable government initiatives and high incidence of cancer to propel market 108
TABLE 55 FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 109
TABLE 56 FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 110
9.4.5 REST OF EUROPE 110
TABLE 57 REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 111
TABLE 58 REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 111
9.5 ASIA PACIFIC 112
FIGURE 26 ASIA PACIFIC: CANCER PREVALENCE, 2012–2020 112
FIGURE 27 ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022) 113
TABLE 59 ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 60 ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 114
TABLE 61 ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 62 ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 63 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
9.5.1 ASIA PACIFIC: RECESSION IMPACT 116
9.5.2 JAPAN 116
9.5.2.1 Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market 116
TABLE 64 JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 117
TABLE 65 JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 118
9.5.3 CHINA 118
9.5.3.1 Increasing number of government initiatives and growing geriatric population to drive market 118
TABLE 66 CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 119
TABLE 67 CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 119
9.5.4 INDIA 120
9.5.4.1 Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market 120
TABLE 68 INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
TABLE 69 INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 121
9.5.5 REST OF ASIA PACIFIC 121
TABLE 70 REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 122
TABLE 71 REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 123
9.6 REST OF THE WORLD 123
TABLE 72 REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 73 REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 74 REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 75 REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 126
9.6.1 REST OF THE WORLD: RECESSION IMPACT 126
10 COMPETITIVE LANDSCAPE 128
10.1 OVERVIEW 128
10.2 KEY STRATEGIES/RIGHT TO WIN 128
10.3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET 129
FIGURE 28 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET 129
10.4 REVENUE SHARE ANALYSIS 130
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020–2022 130
10.5 MARKET SHARE ANALYSIS 130
FIGURE 30 ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022 130
TABLE 76 DEGREE OF COMPETITION IN THERANOSTICS MARKET 131
10.6 COMPANY EVALUATION MATRIX 132
10.6.1 STARS 132
10.6.2 EMERGING LEADERS 132
10.6.3 PERVASIVE PLAYERS 132
10.6.4 PARTICIPANTS 132
FIGURE 31 COMPANY EVALUATION MATRIX, 2022 133
10.6.5 COMPANY FOOTPRINT 134
TABLE 77 PRODUCT AND REGIONAL FOOTPRINT 134
10.7 START-UP/SME EVALUATION MATRIX 134
10.7.1 PROGRESSIVE COMPANIES 134
10.7.2 RESPONSIVE COMPANIES 134
10.7.3 DYNAMIC COMPANIES 135
10.7.4 STARTING BLOCKS 135
FIGURE 32 START-UP/SME EVALUATION MATRIX, 2022 135
10.7.5 COMPETITIVE BENCHMARKING 136
TABLE 78 DETAILED LIST OF KEY START-UPS/SMES 136
10.8 COMPETITIVE SCENARIOS & TRENDS 136
11 COMPANY PROFILES 139
11.1 KEY PLAYERS 139
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 ADVANCED ACCELERATOR APPLICATIONS 139
TABLE 81 ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW 139
11.1.2 BAYER AG 142
TABLE 82 BAYER AG: COMPANY OVERVIEW 142
FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2022) 142
11.1.3 GE HEALTHCARE 145
TABLE 83 GE HEALTHCARE: COMPANY OVERVIEW 145
FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 146
11.1.4 SIEMENS HEALTHINEERS AG 150
TABLE 84 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 150
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 151
11.1.5 CARDINAL HEALTH 154
TABLE 85 CARDINAL HEALTH: COMPANY OVERVIEW 154
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2022) 155
11.1.6 PHILIPS HEALTHCARE 157
TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW 157
FIGURE 37 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022) 158
11.1.7 CANON INC. 160
TABLE 87 CANON INC.: COMPANY OVERVIEW 160
FIGURE 38 CANON INC.: COMPANY SNAPSHOT (2022) 161
11.1.8 CURIUM 163
TABLE 88 CURIUM: COMPANY OVERVIEW 163
11.1.9 LANTHEUS 166
TABLE 89 LANTHEUS: COMPANY OVERVIEW 166
FIGURE 39 LANTHEUS: COMPANY SNAPSHOT (2022) 166
11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES 168
TABLE 90 NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW 168
11.1.11 ECKERT & ZIEGLER 171
TABLE 91 ECKERT & ZIEGLER: COMPANY OVERVIEW 171
FIGURE 40 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022) 171
11.1.12 PHARMALOGIC 174
TABLE 92 PHARMALOGIC: COMPANY OVERVIEW 174
11.1.13 ECZACIBAŞI-MONROL 176
TABLE 93 ECZACIBAŞI-MONROL: COMPANY OVERVIEW 176
11.1.14 ACROTECH BIOPHARMA, INC. 178
TABLE 94 ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW 178
11.2 OTHER PLAYERS 179
11.2.1 THERMO FISHER SCIENTIFIC INC. 179
11.2.2 GLOBAL MEDICAL SOLUTIONS 180
11.2.3 SHINE TECHNOLOGIES, LLC 181
11.2.4 ISOTOPIA MOLECULAR IMAGING LTD. 182
11.2.5 INSTITUTE OF ISOTOPES 183
11.2.6 CHINA ISOTOPE & RADIATION CORPORATION 184
11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD. 185
11.2.8 ATOMVIE 186
11.2.9 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH 186
11.2.10 TELIX PHARMACEUTICALS LIMITED 187
11.2.11 BLUE EARTH DIAGNOSTICS 187
11.2.12 SOFIE BIOSCIENCES 188
11.2.13 THERAGNOSTICS 188
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 189
12.1 DISCUSSION GUIDE 189
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 193
12.3 CUSTOMIZATION OPTIONS 195
12.4 RELATED REPORTS 195
12.5 AUTHOR DETAILS 196